We're moving into a time of year that’s been difficult for bulls, historically. However, if the market does sell off, Cramer won't cry.» Read More
NEW YORK, Oct 21- Former SAC Capital portfolio manager Mathew Martoma on Tuesday lost a bid to stay out of prison while he appeals his insider trading conviction, three weeks before he is due to begin serving a nine-year sentence. District Judge Paul Gardephe in New York denied Martoma's request for bail pending his appeal, as well as a separate request to delay his...
Oct 20- Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV, Bloomberg reported, citing people familiar with the matter. Other bidders for the Belgian consumer healthcare company include Perrigo Co and private German drugmaker Boehringer Ingelheim GmBH, the sources told Bloomberg.
NEW YORK, Oct 15- A federal judge in Manhattan will soon have to weigh in on how the family of a convicted insider trader should live while the man spends nearly a decade in federal prison. The wife of Mathew Martoma, who was caught using secret tips to trade two stocks while working for SAC Capital Advisors, asked a court on Wednesday to let her keep the couple's $2.2...
If the SEC rules in their favor, the investors could seek a portion of the $602 million the SEC collected in a settlement from a division of SAC Capital Advisers after former portfolio manager Mathew Martoma was caught trading on secret tips. The SEC will also be weighing in on a long-running debate over whether insider trading is a victimless crime.
Sept 29- Amag Pharmaceuticals Inc entered the women's healthcare business by acquiring privately held Lumara Health Inc for $675 million in its biggest deal ever, sending its shares up as much as 23 percent to a four-year high.
Sept 29- Amag Pharmaceuticals Inc said it would buy privately held women's healthcare company Lumara Health Inc for $675 million in cash and stock, gaining access to the only approved product designed to reduce the risk of preterm birth.
NEW YORK, Sept 8- Mathew Martoma, a former portfolio manager at billionaire Steven A. Cohen's SAC Capital Advisors LP hedge fund, was sentenced on Monday to nine years in prison for engaging in what authorities called the most lucrative insider trading scheme in U.S. history. District Judge Paul Gardephe in New York also ordered Martoma, 40, to forfeit $9.3 million.
NEW YORK, Sept 4- A federal judge on Thursday refused to throw out the insider trading conviction of former SAC Capital portfolio manager Mathew Martoma, saying the trial evidence "overwhelmingly demonstrated Martoma's guilt."
NEW YORK, Aug 14- A federal judge rejected billionaire investor Steven A. Cohen's bid to dismiss lawsuits by Elan Corp and Wyeth shareholders who claimed they lost money because his firm SAC Capital Advisors LP conducted insider trading in the drugmakers' stocks.
DUBLIN, July 30- Ireland is in the firing line from Washington again for luring U.S. companies to its shores for tax benefits, but despite contrite noises coming from Dublin, it has too much to lose to discourage U.S. firms bent on shifting their tax domiciles.
However, the report from the Generic Pharmaceutical Association said REMS have been used to prevent generic drugmakers from getting branded medicine to test their own versions, which is required to win FDA approval.
Medical technology group Medtronic Inc said last month that it plans to buy Covidien Plc, a rival based in low-tax Ireland. The research service said other inversions have been done in the past decade by Mallinckrodt Pharmaceuticals, Perrigo Co Plc, Actavis Plc and other companies, many of them rebasing for tax purposes to Ireland.
NEW YORK, June 27- Mathew Martoma, a former SAC Capital Advisors portfolio manager convicted of insider trading, should be sentenced to a "substantial" term of prison beyond the eight years recommended by probation officers, U.S. prosecutors argued Friday. In court papers filed in New York federal court, prosecutors urged U.S.
Mead Johnson Nutrition Co in 2011 saw its shares fall when stores pulled some powdered versions of its Enfamil product over concerns about infection, although the FDA later said a recall was not needed. The new rule, the FDA said, is aimed at establishing "good manufacturing practices" that many companies have already adopted voluntarily.
Some of Wednesday's midday movers:
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
A couple of stocks stand to gain over the next two weeks, Paul Hickey of Bespoke Investment Group says.
Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?
In his book "Get Rich Carefully," CNBC's "Mad Money" host explains how spotting long-term megatrends can help investors surf the wave of profitability.